Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

The US Food and Drug Administration approved Gomekli (mirdametinib), from SpringWorks Therapeutics, a kinase inhibitor, for adult and pediatric patients two years of age and older with ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...